Religare Enterprises Ltd

Q1 FY27Finance

Religare Enterprises Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book

Q1 FY27 earnings call: what management guided on revenue, margins and order book.

Price₹228

Market cap₹8.0K Cr

P/E161.1

Updated26 Aug 2026

Read4 min read

What the Q1 FY27 call signalled

3 of 4 strong

RevenueRank 2

MarginRank 3

CapexYes

FundraiseYes

Not discussed on this call: order book.

The short version

Care Health Insurance expects strong growth, with a 37% overall GWP increase in Q1 FY27 and retail new business growing over 50%. Care Health Insurance aims to continue market outperformance with 37% growth in GWP and retail growing 45% YoY (Page 7-8).

From Religare Enterprises Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

Rank 2

Care Health Insurance expects strong growth, with a 37% overall GWP increase in Q1 FY27 and retail new business growing over 50%.
Care aims to beat the industry growth rate, which is 32% for retail health, indicating continued market share gains.
Financial services NBFC businesses (Religare Finvest and Housing Finance) plan to grow their loan book significantly, targeting an AUM of INR10,000-15,000 crores with adequate capital (INR1,500 to 2,000 crores) earmarked for growth.
Broking business is in a repair and investment phase with intentions to build a new growth model; Q1 FY27 revenue increased 7% YoY with a 53% increase in PBT.
Overall, Religare Enterprises is focusing on increasing productivity, expanding product offerings, and tapping Tier 2 and Tier 3 markets for growth.
Demerger delays may slightly impact timeline but remain a focus for unlocking shareholder value.

Profitability & Margins

Care Health Insurance aims to continue market outperformance with 37% growth in GWP and retail growing 45% YoY (Page 7-8).
Care plans to improve combined ratio to 100% over next two years, supporting profitability (Page 9).
Financial Services segment (Religare Finvest) is capitalized (~INR1,500-2,000 crores) targeting INR10,000-15,000 crores AUM, indicating growth ambitions (Page 12-13).
Broking business is in a "repair and investment mode" with expected recovery and growth in revenue and profitability in upcoming quarters (Page 13-14).
Overall REL consolidated revenue grew 26% YoY, but PAT was negative this quarter due to reporting standards and investments in growth (Pages 5-6).
RBI regulatory approvals and structural changes like demerger could impact timing of value unlocking and profitability (Pages 8, 17-18).
Management is focused on operational efficiency, productivity gains, and leveraging technology platforms for sustainable earnings growth (Pages 13-14).

See what Religare Enterprises Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Yes

Care Health Insurance raised INR150 crores equity through rights issue in Q1 FY27 and INR200 crores sub-debt in August 2026 to support business growth as per IRDAI norms.
Additional capital infusion planned to maintain solvency ratio at 1.7x; promoters, including Religare Enterprises Limited (REL) and Kedaara, committed to funding as needed.
REL subscribed fully and beyond its quota in rights issues, marginally increasing its stake in Care.
Care aims to deploy raised capital primarily for business growth and profitability enhancement.
Financial services business (NBFC and HFC) is sufficiently capitalized with about INR1,500-2,000 crores of capital earmarked, targeting a book size of INR10,000-15,000 crores.
No current plans for demerger; engaging with regulators before considering value unlocking strategies.
No specific new capex projects disclosed; focus remains on capitalizing existing businesses and growth initiatives.

Top-ranked in Finance

Ranked on what management guided this quarter

5x potential

1Akiko₹466 Cr

Rev 1Mar 1

2Finkurve Fin.₹1.0K Cr

Rev 1Mar 2

3₹286 Cr

Rev 1Mar 2

4₹39.2K Cr

Rev 1Mar 3

5₹25.6K Cr

Rev 1Mar 3

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

Care Health Insurance raised INR150 crores equity through rights issue in Q1 FY27 and an additional INR200 crores via subordinated debt in August 2026; the capital has already been deployed to support growth.
Care plans to maintain a solvency ratio around 1.7x and may raise further capital through equity or subordinated debt as needed to support solvency and growth.
Religare Enterprises typically subscribes fully and sometimes extra in Care’s rights issues; there is a likely upcoming rights issue planned by Care.
Promoters, including Religare Enterprises, have earmarked capital (around INR600 crores) for Care through rights issues and warrants conversion, with remaining INR881 crores of warrants due by March 2027.
No other immediate new fundraising plans mentioned; focus is on regulator approvals for demerger and value unlocking before further capital moves.

See what Religare Enterprises Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The document does not explicitly mention current or expected orderbook or pending orders for Religare Enterprises Limited. However, relevant financial service and business update details that indirectly relate to business growth and plans include: - The NBFC and HFC businesses are capitalized with ambitions for a loan book size of INR10,000 crores to INR15,000 crores. - NBFC capital is about INR1,000 crores, HFC around INR200 crores, with INR250 crores planned topping up. - Focus on business growth and value unlocking subject to RBI approvals. - Broking business saw a rebound with revenue growth and increased client debit book by 78% YoY. - CARE Health Insurance raised equity and sub-debt capital to support expansion. - Legacy loan book recovery efforts underway with a written-off pool of INR350-400 crores within next two years. No direct orderbook or pending order details are provided in the available transcript.

Religare Enterprises Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹2.5K Cr, net profit ₹96 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

What Religare Enterprises Ltd's management said in earlier quarters

Others in Finance this season

Muthoot Finance Ltd (Q1 FY27)
Despite competitive intensity, Muthoot Finance has demonstrated growth; Q1 saw about 6% growth (~INR 9,000 crores). Key concall takeaways from Muthoot Finance…
Mahindra & Mahindra Financial Services Ltd (Q1 FY27)
The company has already seen wheels AUM growth at 11%-12% and non-wheels at 28%-30% in recent quarters. Key concall takeaways from Mahindra & Mahindra…
Akiko Global Services Ltd (Q1 FY27)
Personal loans are growing fastest, with 5%-10% month-on-month growth. Key concall takeaways from Akiko Global Services Ltd's Q1 FY27 earnings call — and how…
Max India Ltd (Q1 FY27)
Care Homes occupancy is improving steadily (e.g., Bannerghatta from 37% to 41%), with potential expansion plans in late FY27. Key concall takeaways from Max…

Compare:vs Bajaj Finance Ltd vs Bajaj Finserv Ltd vs Shriram Finance Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Religare Enterprises Ltd Q1 FY27 results?

What is Religare Enterprises Ltd share price analysis?

Religare Enterprises Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 161.1 with a market cap of ₹7,984 Cr. Investors should review the full earnings analysis for detailed insights.

Is Religare Enterprises Ltd planning capital expenditure?

Care Health Insurance raised INR150 crores equity through rights issue in Q1 FY27 and INR200 crores sub-debt in August 2026 to support business growth as per IRDAI norms.

Keep Religare Enterprises Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.